Interferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway

British Journal of Cancer

Volumn 109, Issue 5, 2013, Pages 1198-1205

  Xie, C ^a   Xie, D Y ^a   Lin, B L ^a   Zhang, G L ^a   Wang, P P ^a   Peng, L ^a   Gao, Z L ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

IFN b; hepatocellular carcinoma; BMSC; FOXO3a; AKT

Indexed keywords

BETA INTERFERON; BROXURIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; BONE MARROW CELL; BONE MARROW MESENCHYMAL STEM CELL; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEPG2; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELIVERY SYSTEM; GENE TARGETING; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; MESENCHYMAL STEM CELL; MODIFIER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; SURVIVAL TIME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BONE MARROW CELLS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG DELIVERY SYSTEMS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON-BETA; LIVER NEOPLASMS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-AKT; RETINOBLASTOMA PROTEIN; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883740345     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.422     Document Type: Article

References (36)

1. Angelucci C, Iacopino F, Ferracuti S, Urbano R, Sica G. (2007) Recombinant human IFN-b affects androgen receptor level, neuroendocrine differentiation, cell adhesion, and motility in prostate cancer cells. J Interferon Cytokine Res 27: 643-652. (Pubitemid 350194561)
2. Aravalli RN, Steer CJ, Cressman EN (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48: 2047-2063.
3. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J (2000) Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 20: 857-866.
4. Chan X, Shi-Bin X, Dong-Ying X, Liang P, Shao-Quan Z, Jun-Qiang X, Zhi-Liang G (2010) Bone marrow mesenchymal stem cell has poor proliferation but non-tumorigenicity in cancer environment. Lab Medicine 41: 551-556.
5. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, Petruzzelli M, Salvatore L, Moschetta A, Simone C (2009) p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha-to FoxO-dependent transcription. Cell Death Differ 16: 1203-1214.
6. Dedoni S, Olianas MC, Onali P (2010) Interferon-b induces apoptosis in human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/Akt pathway. J Neurochem 115: 1421-1433.
7. Einhorn S, Grander D (1996) Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res 16: 275-281. (Pubitemid 26132339)
8. Elzaouk L, Moelling K, Pavlovic J (2006) Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 15: 865-874. (Pubitemid 44473325)
9. Ho KK, Myatt SS, Lam EW (2008) Many forks in the path: cycling with FoxO. Oncogene 27: 2300-2311. (Pubitemid 351501781)
10. Huang H, Tindall DJ (2007) FoxO transcription factors. J Cell Sci. 120: 2479-2487.
11. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP (2002) Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8: 1258-1270. (Pubitemid 35177383)
12. Kim BC (2008) FoxO3a mediates transforming growth factor-beta1-induced apoptosis in FaO rat hepatoma cells. BMB Rep 41: 728-732.
13. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, Lam EW, Burgering BM (2002) Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 22: 2025-2036. (Pubitemid 34224611)
14. Lu M, Ma J, Xue W, Cheng C, Wang Y, Zhao Y, Ke Q, Liu H, Liu Y, Li P, Cui X, He S, Shen A (2009) The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol Oncol Res 15: 679-687.
15. Massague J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19: 2783-2810. (Pubitemid 41739965)
16. Matrone A, Grossi V, Chiacchiera F, Fina E, Cappellari M, Caringella AM, Di Naro E, Loverro G, Simone C (2010) p38a is required for ovarian cancer cell metabolism and survival. Int J Gynecol Cancer 20: 203-211.
17. Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, Barry F, O'Brien T, Zwacka R (2008) Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 12: 2628-2643.
18. Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H (2003) Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther 10: 549-558. (Pubitemid 36842012)
19. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318. (Pubitemid 40524615)
20. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y, Hamada H (2004) Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11: 1155-1164. (Pubitemid 39117311)
21. Natsume A, Mizuno M, Ryuke Y, Yoshida J (1999) Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 6: 1626-1633. (Pubitemid 29465522)
22. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108. (Pubitemid 40372904)
23. Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, Zheng YB, Gao ZL (2011) Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 54: 820-828.
24. Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, Ponnazhagan S (2008) Cancer gene therapy using mesenchymal stem cells expressing interferon-b in a mouse prostate cancer lung metastasis model. Gene Ther 15: 1446-1453.
25. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A (1996) Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 16: 759-764. (Pubitemid 26389112)
26. Sasaki S, Ishida T, Toyota M, Ota A, Suzuki H, Takaoka A, Yasui H, Yamamoto H, Takagi H, Maeda M, Seito T, Tsujisaki M, Shinomura Y, Imai K (2011) Interferon-a/b and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo. PLoS One 6: e19618.
27. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA (2007) Concomitant activation of the JAK/STAT, PI3K/Akt, and ERK signaling is involved in leptin-ediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67: 2497-2507. (Pubitemid 46548934)
28. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM, Medema RH (2002) Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22: 7842-7852. (Pubitemid 35217295)
29. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62: 3603-3608. (Pubitemid 34728832)
30. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M (2004) Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96: 1593-1603. (Pubitemid 39534883)
31. Tang ED, Nuñez G, Barr FG, Guan KL (1999) Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 274: 16741-16746.
32. Wilderman MJ, Sun J, Jassar AS, Kapoor V, Khan M, Vachani A, Suzuki E, Kinniry PA, Sterman DH, Kaiser LR, Albelda SM (2005) Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res 65: 8379-8387. (Pubitemid 41330604)
33. Wong VL, Rieman DJ, Aronson L, Dalton BJ, Greig R, Anzano MA (1989) Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines. Int J Cancer 43: 526-530. (Pubitemid 19092340)
34. Xu L, Xie K, Fidler IJ (1998) Therapy of human ovarian cancer by transfection with the murine interferon beta gene: role of macrophage-inducible nitric oxide synthase. Hum Gene Ther 9: 2699-2708. (Pubitemid 29027013)
35. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, Villunger A, Mak TW. (2006) FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 203: 1657-1663. (Pubitemid 44036270)
36. Zhang F, Lu W, Dong Z (2002) Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-b gene therapy in nude mice. Clin Cancer Res 8: 2942-2951. (Pubitemid 35025743)